We have utilized a recombinant adeno-associated viral (AAV) 
Introduction
Novel strategies are needed for the treatment of malignant brain tumor (glioblastoma multiforme, GBM), which is the most common type of brain tumor. The median survival time of patients with GBM is less than 2 years, despite multi-modality treatments with extensive surgical resection, radiotherapy, chemotherapy or immunotherapy. In order to overcome this highly lethal neoplasm, molecular neurosurgery with gene therapy tools has been the subject of investigation since 1992, 1 along with novel pharmaceutical interventions such as antiangiogenesis, and immunotherapy. 2, 3 Many of the gene therapy approaches are based on previously established anti-neoplastic principles, including the use of prodrug/suicidal genes, tumor suppressor genes and immune-enhancing cytokine genes. [4] [5] [6] [7] [8] [9] Recently, the antiangiogenic strategies have also been investigated for cancer gene therapy. 10 Angiogenesis, the outgrowth of new blood vessels from the pre-existing vasculature, is essential for a number of physiological process and pathological conditions. 11, 12 Low-grade gliomas are moderately vascu-larized tumors, whereas high-grade gliomas show prominent neovessel proliferation with high vascular density. It is hypothesized that solid tumors are dependent on angiogenesis for sustained growth, and that antiangiogenic treatment is a promising anti-neoplastic therapy. 13 Cerebral gliomas have been accordingly considered as a suitable candidate for such treatment, which attempts to eradicate or suppress the tumors by interfering with its blood supply. Although multiple factors contribute to the ultimate vascularization of tumors, some factors are especially relevant to gliomas. It is possible to effectively inhibit tumor growth by inhibiting the key factors in tumor vascularization. 10 Experimental evidence indicates that blocking angiogenesis by specific inhibitory agents is associated with tumor regression in animals with different types of neoplasia. The promising anti-angiogenic agents include (1) naturally occurring inhibitors of angiogenesis such as angiostatin and endostatin; (2) specific inhibitors of endothelial cell growth such as TNP-470 and thalidomide; (3) agents neutralizing angiogenic peptides such as antibodies or soluble receptors against FGF and VEGF; (4) anti-adhesion molecules and antibodies. Therefore, anti-angiogenic therapy represents one of the promising new approaches for anticancer therapy and it is already in early clinical trials. 12, 14, 15 Angiostatin is a potent inhibitor of angiogenesis in tumor growth and metastasis. It is derived from plasmin-3 ogen as a biologically active fragment containing the kringle domains 1-4. It specifically inhibits endothelial cell growth, [16] [17] [18] but has no direct effects on other cell types including tumor cells in vitro. Systemic administration of purified angiostatin efficiently suppresses malignant glioma growth in vivo. 19 Recent studies have demonstrated that retroviral and adenoviral vectors that carry the angiostatin cDNA can be used to inhibit endothelial cell growth in vitro and angiogenesis in vivo. Vector-mediated inhibition of tumor angiogenesis resulted in increased apoptosis in endothelial cells, as well as tumor cells, leading to the inhibition of tumor growth. These studies support the concept of dormancy therapy [20] [21] [22] [23] [24] [25] [26] [27] and rationalize the role of angiostatin gene transfer as a novel therapeutic strategy for malignant brain tumors.
Adeno-associated virus (AAV) offers many of the desirable features of retroviruses and adenovirus but without some of their potential drawbacks for application in gene therapy. 28 AAV is a non-pathogenic, replicationdefective single-stranded DNA virus, capable of persisting either by integrating into the host genome or retaining as an episome. [29] [30] [31] The recombinant AAV vectors can transduce both dividing and non-dividing cells in vitro and in vivo. 32 Efficient and long-term in vivo transduction and the lack of both cytotoxicity and cellular immune responses are the hallmark features of AAVmediated gene transfer. [33] [34] [35] [36] [37] Although AAV vectors have been extensively used in gene therapy for genetic and metabolic diseases, few studies have used this vector system for cancer gene therapy. 34, [38] [39] [40] [41] [42] In this report, we have used the AAV vector carrying the cDNA of an anti-angiogenic protein, angiostatin, to treat the highly malignant and highly angiogenic brain tumor derived from a C6 glioma cell line in a rat model. Intratumoral injection of the AAV-angiostatin vector resulted in significant tumorsuppressive effects. In addition, we have investigated the combined gene therapy of adenoviral vector carrying the suicidal thymidine kinase gene with the AAV-angiostatin vector. The combined gene therapy offered the best tumor-suppressive effects along with improved survival rate of the tumor-bearing rats.
Results

In vitro biological effects of angiostatin from stably transfected and AAV-angiostatin-infected C6 glioma cells
To demonstrate vector-derived angiostatin expression in vitro or in vivo, an HA tag sequence was added to the 3'-end of the angiostatin cDNA to distinguish from the endogenous protein. The angiostatin-HA/pCEP4 expression plasmid was used to stably transfect the C6 glioma cells. Using lysine-sepharose binding method followed by immunoblotting with an anti-HA antibody, we had detected a 50-60 kDa protein from the culture medium, as well as cell lysate (Figure 1a, lanes 3 and 6) . Due to glycosylation of the angiostatin in mammalian cells and the addtion of the HA tag, the apparent molecular weight of the angiostatin is larger than the theoretically deduced one of 38 kDa. The presence of abundant angiostatin in the conditioned medium of stably tranfected C6 glioma cells indicated its efficient secretion ( Figure 1a, lane 3) . In addition, no significant differences in growth rates were observed among the parental C6 glioma cells, the empty-vector transfected C6/pCEP4 cells, and the C6/angiostatin-HA/pCEP4 cells (data not shown). Furthermore, AAV-angiostatin vector infected C6 glioma cells produced significant amounts of angiostatin protein in both conditioned medium and cell lysate (Figure 1b, lanes 3 and 6) . However, the uninfected cells (Figure 1b, lanes 1 and 4) and the control AAV-GFP vector infected cells (Figure 1b , lanes 2 and 5) had no detectable angiostatin-HA, indicating that the AAV-angiostatin vector is capable of infecting the C6 glioma cells and that the angiostatin protein can be effectively secreted.
To study the biological effects of angiostatin in vitro, the conditioned media from C6 glioma cells, C6/pCEP4 cells, and C6/angiostatin-HA/pCEP4 cells were add to the human umbilical vein endothelial (HUVE) cells culture to see if the HUVE cells growth could be inhibited.
While the conditioned medium from both C6 and C6/pCEP4 control cells did not make significant difference, the conditioned medium from C6/angiostatin-HA/pCEP4 cells caused significant growth retardation of HUVE cells (data not shown), suggesting that the secreted angiostatin was biological active in inhibiting endothelial cell growth in vitro.
To test if AAV vector gene transfer can exert growth inhibition on the human HUVE cells cultures, AAVangiostatin or AAV-GFP vectors were used to directly infect the HUVE cells. Surprisingly, no significant difference in growth rate was observed. This failure was later attributed to the low transduction efficiency (Ͻ1%) of HUVE cells by AAV vectors. On the other hand, since AAV vectors can effectively infect 293 cells, the conditioned media from AAV-angiostatin or AAV-GFP infected 293 cells were collected 3 days after infection. Strong inhibition of HUVE cells growth was achieved by medium from AAV-angiostatin infected 293 cells, but not from AAV-GFP infected or uninfected 293 cells ( Figure  1c ). This result confirmed the in vitro biological functionality of AAV-derived angiostatin protein in inhibiting endothelial cell growth.
Suppression of tumor growth by stably transfected angiostatin gene in C6 glioma cells
To evaluate whether the angiostatin gene is functional in vivo in inhibiting angiogenesis of the gliomas, we initially carried out a test using the stably transfected C6/angiostatin-HA/pCEP4 cells, along with the control parental C6 cells and the C6/pCEP4 cells that harbored an empty plasmid vector. The glioma cells were implanted intracranially, and their in vivo growth rates were investigated in a time course. The tumors were harvested from the rat brains at a weekly interval to measure the tumor size and vascularization, while the animals in the control groups all expired over the 3 weeks due to excessive tumor burden (Figure 2a ). Histopathological analysis revealed that the gliomas derived from C6 and C6/pCEP4 cells were large, red, hypervascularized with petechia, and central necrosis. However, C6/angiostatin-HA/pCEP4 derived gliomas were generally small, pale, with fewer visible surface blood vessels. The average tumor sizes at the end of third week after glioma implantation were 103.33 ± 4.37 mm 3 for C6/angiostatin-HA/pCEP4 cells, 797.22 ± 6.6 mm 3 for C6 cells, and 756 ± 24.82 mm 3 for C6/pCEP4 respectively ( Figure 2a ). In another experiment, the bystander effects were examined by mixing the C6/angiostatin-HA/pCEP4 cells with either the parental C6 cells or the C6/pCEP4 cells in an equal ratio before tumor implantation. Strong in vivo inhibition of both C6 and C6/pCEP4 glioma growth was also observed in the mixing experiment by the C6/angiostatin-HA/pCEP4 cells (Figure 2b ), suggesting that the secreted angiostatin can render the 'bystander' effect in inhibiting tumor neovessel formation.
Immunohistochemical staining of the tumor thin sections revealed significantly fewer microvessels in the C6/angiostatin-HA/pCEP4 glioma when compared with the C6 and C6/pCEP4 gliomas (Figure 2c ), as determined by direct microvessel counting of the Factor VIII receptor antigen-positive vessels. On the second week after tumor implantation, the blood vessel counts in C6/angiostatin-HA/pCEP4 glioma were 16.5% (13.3/80.4) of those seen in C6 glioma, and the vessel counts decreased to 13.7% (16.8/123 ) by the third week ( Figure 2c ). In addition, TUNEL staining showed that the apoptotic indexes were higher in the C6/angiostatin-HA/pCEP4 glioma than those of C6 and C6/pCEP4 gliomas at 3 weeks following intracranial injection of the tumor cells (Figure 2d ), supporting the observation in numerous previous studies by others.
20,25,41
Suppression of tumor growth by intratumoral injection of AAV-angiostatin vector
To assess whether AAV-angiostatin vector could inhibit angiogenesis and tumor growth in vivo, the same C6 glioma/Wistar rat model was used as in the aforementioned experiments. One week after implantation of 5 × 10 5 of the C6 glioma cells into the rat brain, either AAVangiostatin vector, PBS saline or AAV-GFP vector was injected into the existing brain tumor. Starting from 2 weeks after tumor implantation, groups of rats were killed every week for evaluation. The tumor volumes on the third week after implantation were 87.2 ± 35 mm 3 in AAV-angiostatin treated rats, 797.24 ± 6.62 mm 3 in PBS saline-treated rats, and 741 ± 30.24 mm 3 in AAV-GFP treated rats, respectively (Figure 3a and b).
We have also monitored the survival time course of the tumor-bearing rats. All of the Wistar rats which received C6 glioma cell implantation and were treated with PBS saline or AAV-GFP vector died within 23 days due to excessive tumor burden (Figure 3c ). In the same period, however, more than 60% of the AAV-angiostatin vector treated rats were still alive. On the 35th day after C6 glioma cell implantation, 40% of the AAV-angiostatin vector treated rats survived and continued to survive for 6 months, which was the duration of the experiments (Figure 3c ). These rats had tiny tumor nodules in the brains upon postmortem examination, demonstrating that the AAV-angiostatin vector can efficiently suppress glioma growth in vivo.
Immunohistochemical staining of the tumors with antivon Willebrand factor antibody on the first, second and third week after glioma implantation showed that the AAV-angiostatin treatment significantly reduced the number of blood vessels in the tumors when compared with those seen in the PBS saline treated and AAV-GFP treated ones (Figure 4a ). On the second week, the blood vessel counts were 34.3% (33.4/97.4) of those in PBSsaline treated C6 glioma. On the third week, the vessel counts were 25.1% (28.4/113) of the PBS-saline-treated C6 glioma (Figure 4b) . Consistently, the apoptotic indexes of the AAV-angiostatin-treated tumors were higher than those seen in the PBS-saline-treated and AAV-GFPtreated gliomas by the TUNEL staining (Figure 4c) . The increased tumor cell apoptosis may have contributed to the tumor shrinkage during the course of gene therapy.
Combined gene therapy with adenovirus HSV-tk vector and AAV-angiostatin vector
Anti-angiogenic therapy is tumorstatic instead of tumoricidal, because it exerts its function directly on the endothelial cells and indirectly on the cancer cells. A combination of two different strategies employing distinct mechanisms, for example, anti-angiogenic and suicidal gene therapies, may provide additive benefits. Based on this rationale, we investigated the combined gene therapy using both the adenoviral vector carrying the thymidine kinase (tk) gene (AdRSVtk) and the AAV vector car- rying the angiostatin gene (AAV-angiostatin) to treat the C6 glioma in the Wistar rat model. First, a time course of tumor growth was done on the tumor-bearing rats undergoing gene therapies with the combined treatment of AdRSVtk and AAV-angiostatin vectors, or with a single vector treatment and without therapeutic treatment. Three weeks after implantation, the C6 glioma tumors without any therapeutic gene treatment were very large and occupied nearly half of the cranial cavity. However, the tumors in the gene therapy groups were generally smaller and pale in color with fewer visible surface blood vessels, especially in the groups receiving anti-angiogenic therapy. For example, the tumor volumes on the third week after C6 cell implantation were respectively 796 ± 29.28 mm 3 in the untreated control group, 101 ± 1.95 mm Gene Therapy (Figure 5a ). On the fifth week after implantation, the tumor volumes in the surviving animals of the above groups were measured at 22 ± 3.5 mm 3 , 19 ± 1.0 mm 3 , and 3.3 ± 0.96 mm 3 , respectively (Figure 5a ). All the AdRSVtkinjected animals also received prodrug ganciclovir treatment at a dosage of 7.5 mg/kg body weight twice a day to achieve the tumor-killing effect.
Next, the survival time of the combined gene therapy regimen was also investigated. All the tumor-bearing rats without vector injection and prodrug ganciclovir treatment died within 3 weeks. However, about 20% of the rats survived more than 50 days as a result of AdRSVtk plus ganciclovir treatment. About 30% of the rats survived for the same period as a result of AdRSVtk and AAV-GFP co-injection and ganciclovir treatment. As expected, the 50-day survival rate increased to 55% in the AdRSVtk and AAV-angiostatin co-injected, ganciclovir treated group. The long-term survival rate in the AAVangiostatin alone treated group was 40% (Figure 3c ), while the dual AdRSVtk and AAV-angiostatin vector treated rats had a survival rate of 55% (Figure 5b) . These results clearly demonstrated that the combined suicidal and anti-angiogenic gene therapy provided additive effects in inhibiting glioma growth. If it were not due to the toxicity of the ganciclovir regimen, the survival rate of the combined gene therapy could have been higher. From our previous experience, a ganciclovir dose of 30 mg/kg body weight twice a day intraperitoneally was 
mm) of a rat brain which had been implanted with C6 glioma cells for 14 days and received an intratumoral injection of AAV-angiostatin on the seventh day after tumor implantation. The tumor was smaller than the one on the day of vector injection, and much smaller than the PBS-treated tumor on day 14. (c) Survival time of the tumor-bearing rats with or without AAVangiostatin treatment. One hundred percent of Wistar rats received C6 glioma cells implantation without vector injection and all died within 3 weeks, and those received AAV-GFP injection also died by 23 days. However, the AAV-angiostatin-treated group had a 40% survival rate for over 6 months after C6 glioma cell implantation.
very toxic. Nearly 90% of the rats died due to bleeding tendency. A lower dose of 15 mg/kg twice a day was still toxic enough to kill 50% of the rats. When the dose of ganciclovir was decreased to 7.5 mg/kg twice a day, about 75% of the rats survived the regimen, while lower doses did not render any tumor-killing effect.
Discussion
Gene therapy to inhibit neovessel formation in the tumors is a promising and feasible anti-cancer strategy. Such a strategy acts on the blocking of blood supply to the tumors, but not directly on tumor cells per se. Therefore, a sustained delivery of the anti-angiogenic factor(s) is essential for the success of tumor growth suppression. Gene transfer of angiostatin represents a highly viable alternative strategy to the direct protein delivery methods of angiogenic inhibitors. 43 Previous studies using purified angiostatin protein to treat malignant glioma 19, 20, 24, 44, 45 showed its effectiveness, but also suffered drawbacks. Direct protein delivery as a pharmaceutical reagent has formidable limitations to overcome in treating malignant brain tumor. First, if given peripherally as bolus doses, it is ineffective at maintaining a sustained therapeutic concentration at the brain tumor sites. Repeated high-dose protein injections might induce adverse immunological problems such as anaphylactic shock, serum sickness, or even some specific antibody formation. Second, frequent intraparenchymal (intratumoral) injections of these proteins are technically impractical and may also induce certain complications such as infections and hemorrhages. The half-lives of these proteins are short when given intraventricularly, and the maintenance of protein concentrations is difficult. Continuous indwelling infusion devices (electronic micropump) is under investigation and expensive. Recently, implantation of biological microspheres, which embedded cells secreting anti-angiogenic factors, showed promise on brain tumor therapy. 46 On the other hand, Gene Therapy 47 may also offer an efficient modality of achieving persistent intratumoral or local secretion of these therapeutic proteins. The results from our study support the rationale of gene therapy for malignant brain tumors using the anti-angiogenic gene(s).
Figure 4 Immunohistochemical and TUNEL staining of brain tumors from rats with or without AAV-angiostatin treatment. (a) Microvessel density in the gliomas revealed by immunohistochemical staining of the tumor thin sections with antibody against von Willebrand factor. AAVangiostatin-treated tumors had a significant reduction in the number of blood vessels when compared with those seen in the PBS
In this report, we have shown that the genetically modified C6 glioma, which secreted high levels of angiostatin in vitro, can suppress tumor growth and prolong the survival of the tumor-bearing animals. Some tumor shrinkage effect and bystander effect were also observed in the angiostatin-expressing C6 gliomas. The reduction of tumor growth and tumor sizes may be associated with decreased numbers of tumor vessels and increased tumor cell apoptotic index. However, using the genetically modified glioma cells is not a practical choice to treat brain tumors in a clinical setting. On the other hand, a single intratumoral injection of AAV-angiostatin vector was also able to dramatically inhibit the primary tumor growth and prolonged the survival time in the C6/Wistar rats model. The reduction of tumor growth and tumor size were associated with the decreased numbers of tumor vessels (Figures 3a and 4a) , consistent with the previous findings by others. 20, 41 These results support the observation in another study 24 using recombinant adenoviral vector carrying the N-terminal fragment of human plasminogen in a C6/athymic murine model with subcutaneous tumors. 24 Brain tumors derived from C6 glioma is highly vascularized due to the overexpression of vascular endothelial growth factor (VEGF). 48 Here we have provided the first evidence of using the AAV vector carrying the angiostatin gene to treat the malignant glioma in vivo. AAV gene therapy effectively inhibited the formation of vascular network in the Wistar rat model of C6 glioma. Thus, the use of AAV vectors carrying the antiangiogenic genes represent a promising and practical anti-cancer therapy. This notion is further supported by the fact that AAV vectors can offer efficient and sustained transgene expression in the absence of vector toxicity. If equipped with an inducible gene expression system 49 that can be turned off when not needed, intratumoral injection of the AAV vector should be a safe and efficient method of choice for local delivery of the transgene product.
Since anti-angiogenic strategy could not completely eradicate the tumors, and only less than half of the tumor-bearing animals had long-term survival after AAV-angiostatin therapy, we explored a combined gene therapy using both adenoviral and AAV vectors carrying the thymidine kinase gene and angiostatin gene. These two genes act via different mechanisms. One kills the tumor cells directly, while the other blocks the blood supply to the tumor mass. In addition, AAV vector transduction efficiency should be enhanced by the adenoviral vector. 50, 51 Our study indeed demonstrated an additive anticancer effect by the combined gene therapy strategy. The long-term survival rate of the tumor-bearing rats after the combined AdRSVtk and AAV-angiostatin treatment increased to 55% (Figure 5b ), while the survival rate was 40% in the group treated only with AAV-angiostatin (Figure 3c) , and 20% in the AdRSVtk treatment group (Figure 5b) . In addition to the improved survival rate, the combined therapy also offered best tumor-suppressive effects. For example, in the third week after C6 glioma cell implantation, the tumor volumes in the AdRSVtktreated group and the AdRSVtk plus AAV-angiostatintreated group were respectively 12.7% and 7.6% of the control C6 glioma group, which did not undergo any therapeutic intervention (Figure 5a ). Other combined therapeutic strategies, eg angiostatin plus radiation therapy 45 or the delivery of more than one angiostatic factor, 52, 53 could also synergize the tumor-suppressive effects. We have recently explored systemic delivery of angiostatin by injection of the AAV-angiostatin vector into the skeletal muscle tissues. Secretion of angiostatin protein from the muscle into the blood stream effectively suppressed human U87MG glioma tumor growth in the brain of nude mice (Ma et al, unpublished data) .
In summary, our studies have demonstrated a new potential of AAV vectors in the application of anti-angiogenic strategy to treat the malignant brain tumors, particularly, in combination with other therapeutic interventions. Additional studies are warranted to further explore the AAV vectors in different cancer models and eventually in human clinical trials.
Materials and methods
Establishment of permanent glioma cell lines expressing angiostatin and AAV vectors carrying the angiostatin gene
Mouse angiostatin cDNA was amplified by PCR from the mouse plasminogen cDNA (ATCC 63112, Manassas, VA, USA) using two oligonucleotide primers (5'-ACGAAGCT TGGATCCATGGACCATAAGGAAGTA-3') and (5'-ACGTCTAGAGGATCCTTAGAGGCTAGCGTAATCCG GAACATCGTATGGGTATGTGGGCAATTCCACAACA-3'), corresponding to mouse plasminogen amino acid residues 1-6 and 461-466 with an HA-tag. 21 The PCR-amplified cDNA fragment was cloned into pGEM-T vector system (Promega, Madison, WI, USA) and the DNA sequence was confirmed. Subsequently, the angiostatin fragment was excised by BamHI digestion and cloned into an expression vector pCEP4 (Invitrogen, Carlsbad, CA, USA), resulting in an expression plasmid angiostatin-HA/pCEP4. To construct the AAV-angiostatin vector, two additional primers (5'-AAGGAAAAAAGCGGCCG CATGGACCATAAGGAAGTA) and (5'-TTTTCCTTTTG CGGCCGCTTAGAGGCTAGCGTAATCCGGAACATCG TATGGGTATGTGGGCAATTCCACAACA) were designed. The angiostatin fragment was PCR amplified, digested with NotI and cloned into the NotI site of pXX-UF1 expression vector. 54 A standard triple-plasmid transfection method was used to produce AAV vectors. 55, 56 The AAV vectors were purified by double-CsCl centrifugation and the titers were determined by dot blot assay in the range of 1.0 to 3.0 × 10 13 viral particles/ml. To make glioma cell lines that stably secrete angiostatin-HA, the angiostatin-HA/pCEP4 plasmid was transfected into C6 glioma cells (American Type Culture Collection, Rockville, MD, USA). The empty vector plasmid pCEP4 was also used to generate control glioma cell lines. Four weeks after hygromycin selection (400 g/ml), resistant clones were selected. The growth rates of these cells (the parental C6, C6/pCEP4, and C6/angiostatin-HA/pCEP4) were measured every 2 days. Immunoprecipitation/ Western blot assay was performed using the cell lysate and conditioned medium to determine the angiostatin expression and secretion as described next. 
Immunoprecipitation/Western blot assay
The parental C6 glioma cell and the stable transfectants C6/pCEP4 cell, and C6/angiostatin-HA/pCEP4 cell were seeded (1 × 10 5 cells) into 10-cm plates and cultured for 5 days. To test the AAV-angiostatin vector expression, 10 l of AAV-angiostatinvector (1 × 10 11 viral particles), or the control AAV-GFP vector (1 × 10 11 viral particles) were used to infect C6 glioma cells (2 × 10 6 ) in 10-cm plates and incubated for 5 days. The cell lysate and conditioned medium were separately collected for analysis. The conditioned media (5 ml) were harvested from each plate and incubated overnight at 4 o C with 150 l of 50% lysinesepharose in 50 mm Tris-HCl, pH 8.0. The cell lysates were also treated by the same method. The bound materials were released by adding 50 l of SDS sample buffer followed by heating samples at 95 o C for 3 min. The samples were separated on a 10% SDS polyacrylamide gel and transferred on to nitrocellulose membrane. The membrane was incubated for 30 min at room temperature in a blocking buffer (5% low fat milk, 150 mm NaCl, and 20 mm Tris-HCl, pH 7.5), and was then incubated with a rabbit antibody against the HA tag (Covance, Richmond, CA, USA). A secondary antibody, horseradish peroxidase (HRP)-conjugated anti-rabbit IgG, was used to detect the primary antibody. The blot was developed against X-ray film with the chemiluminescence reagent plus kit (New Life Science Products, Boston, MA, USA).
Proliferation assay of HUVE cells
According to O'Reilly et al, 16 human umbilical vein endothilial (HUVE) cells (American Type Culture Collection, CRL1730) were seeded at a density of 1 × 10 5 in six-well plates and cultured for 1 day. Subsequently 1.5 ml of conditioned media collected from different angiostatinexpressing C6 glioma cells or control cells (see the preceding sections for details) were added to individual wells of HUVE cells culture. The UVEC cells were trypsinized every 2 days for counting the cell number in triplet, and were continuously passaged in the fresh conditioned media from different C6 gloma cells and the control cells.
Intracranial tumor growth of the glioma cells
Six to 8-week-old male Wistar rats were anesthetized with ketamine (20 mg/kg) and placed in a stereotactic frame (Stoelting, Wood Dale, IL, USA). A burr hole was drilled in the skull 1 mm anterior and 2 mm lateral to the bregma to expose the dura. A microliter syringe (Hamilton, Reno, NV, USA) was fitted with a 27-gauge needle and connected to the manipulating arm of the stereotactic frame were used for glioma tumor cell injection. Totally 5 × 10 5 of the parental C6 glioma cells or different genetically modified cells (C6/pCEP4 cells, and the angiostatin-expressing C6/angiostatin-HA/pCEP4 cells in 5 l of 1 × PBS) were injected into the left striatum area of rat brain at a depth of 3.5 mm from the dura for a 5-min period. The needle was left in place for 10 min and then withdrawn slowly over a further 10 min. In addition, different combination of the parental C6 cells and the genetically modified cells (C6:C6/angiostatin-HA/pCEP4 in a 1:1 ratio at a total number of 5 × 10 5 /5 l; and C6/pCEP4:C6/angiostatin-HA/pCEP4 in a 1:1 ratio at a total number of 5 × 10 5 /5 l) were also injected into the brain to evaluate the bystander effect. After gliGene Therapy oma cell injection, the scalp wound was closed with 3-O nylon sutures. The rats were killed at 7 , 14 and 21 days after tumor implantation and perfused intracardially with 150 ml of warm normal saline and followed by 150 ml of 4% paraformaldehyde. The brains were removed, and serial coronal sections (1 mm) were performed by the rat brain slicer. These slices were scanned into the computer and the tumor areas were measured using UTHSCSA: Image Tool for Windows software (The University of Texas Health Science Center in San Antonio, USA). Actual volume of the tumor mass was derived from the tumor area (mm 2 ) × number of slices × thickness of slices (1 mm). Representative slices were selected, cryoprotected with 20% sucrose in PBS and frozen in Tissue-Tek embedding medium (Electron Microscopy Science, Fort Washington, PA, USA). The brain slices were sectioned at 4 m in thickness for hematoxylin/eosin staining and for other studies including immunohistochemical (factor VIII antibody and PCNA) and TUNEL staining.
Intratumoral gene therapy with the AAV vector carrying angiostatin gene
Seven days after C6 glioma cell implantation as described above, the same coordinates were used for the injection of the AAV viral vectors (5 l, 5 × 10 11 viral particles) except that the needle was placed 1 mm deeper than the previous tumor cells injection site. The AAV viral vectors were delivered to six sites, 0.5 mm apart, along the needle track as the needle was withdrawn with a volume of approximately 0.8 l at each of the six sites over 10 min. The needle was left in the tissue for an additional 5 min and then was slowly withdrawn. The tumor biology was similarly examined as described in the previous section.
Combined gene therapy with an adenoviral vector carrying the HSV-tk (thymidine kinase) gene and an AAV vector carrying the angiostatin gene
A replication-defective adenoviral vector (AdRSVtk) with an RSV promoter driving the HSVtk gene was propagated in 293 cells (a human fetal embryonic kidney cell line), obtained from the American Type Culture Collection. The viral vector titers were determined by plaque assay on 293 cells. With the same methods described earlier, two different viral vectors (AdRSVtk and AAVangiostatin-HA) were injected alone or in combination into the pre-existing C6 gliomas, which were implanted 7 days earlier (at day 0) with a dose of 5 × 10 5 cells/5 l. The experimental rats were divided into four groups. 'Group 1' received intratumoral sham injection (5 l of 1 × PBS) on day 7, and then received intraperitoneal sham injection (500 l of 1 × PBS) daily from day 8 to day 17. 'Group 2' received intratumoral injection of AdRSVtk (4.8 × 10 8 p.f.u./5 l) on day 7, and then received ganciclovir treatment (GCV; 7.5 mg/kg; twice a day) from day 8 to day 17. 'Group 3' received intratumoral injection of both AdRSVtk (4.8 × 10 8 p.f.u./5 l) and control AAV-GFP vector (5 × 10 10 viral particles/5 l) on day 7, and then received GCV treatment (7.5 mg/kg; twice a day) from day 8 to day 17. 'Group 4' received intratumoral injection of both AdRSVtk (4.8 × 10 8 p.f.u./5 l) and AAV-angiostatin vector (5 × 10 10 viral particles/5 l) on day 7, and then received GCV treatment (7.5 mg/kg; twice a day) from day 8 to day 17. In 'Group 3' and 'Group 4', the AdRSVtk and AAV-GFP or AAV-angiostatin (5 × 10 viral particles/5 l) vectors were pre-mixed in 10 l total volume and then delivered at six sites, 0.5 mm apart, along the needle track. After intratumoral injection, the scalp wound was closed with 3-O nylon sutures. Twelve hours after the vector injections, the animals were treated with GCV intraperitoneally twice a day for the next 10 days, while the 'Group 1' control was treated with 1 × PBS daily. The tumor biology was similarly examined as described in the previous section.
Histological and immunohistochemical staining
For the purpose of assessing brain tumor vascularity and growth characteristics, tissue sections were evaluated using antibodies to factor VIII-related antigen (von Willebrand factor), and visualized with a streptavidin-peroxidase complex. According to the methods described by Tanaka et al, 20 all representative tumor tissues were studied. At least five thin slices were made from tumor and used for quantitative immunohistochemistry. Microvessels were counted under ×200 fields on areas of tumor with the highest density of vascular staining.
